Product Code: ETC6190561 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australias sarcopenia market is gaining attention due to its growing elderly population and associated healthcare burden. Sarcopenia, characterized by progressive muscle loss and weakness, is now recognized as a disease entity. The market encompasses nutritional supplements, resistance training equipment, diagnostic tools, and associated services. Efforts to incorporate sarcopenia screening in geriatric assessments are being encouraged through aged care initiatives and public health policy reforms.
Australia`s sarcopenia market is growing in response to the aging population and heightened focus on geriatric health. Preventive care measures, such as physical rehabilitation and nutritional interventions, are gaining popularity. The incorporation of digital health technologies like wearables and mobile apps for muscle strength monitoring is also influencing the market positively. Healthcare providers are increasingly promoting resistance training and protein supplementation as key interventions.
One of the major challenges in the sarcopenia market is the under-recognition of the condition, particularly in older adults. There is no standardized diagnostic criterion adopted nationwide, which hinders early identification and intervention. Additionally, sarcopenia is not always treated as a primary health issue, often overshadowed by comorbid conditions, making it a low priority in healthcare planning and policy.
The growing aging population makes sarcopenia a compelling market for health-tech investors. Opportunities lie in developing diagnostics, wearable monitoring devices, and health platforms for early detection and management. Fitness centers and rehabilitation service providers focusing on muscle health in seniors can attract impact investment. Nutrition companies can also tap into this market by developing tailored supplements and functional foods aimed at muscle mass preservation.
In the sarcopenia market, Australian government policies currently offer limited support specifically for the treatment of age-related muscle loss. The government focuses more on chronic diseases such as heart disease and diabetes, leaving sarcopenia largely unaddressed. However, with an aging population, there has been growing advocacy for policies that integrate sarcopenia management into national health strategies, such as in the areas of aged care and preventative healthcare. There is potential for the government to offer incentives for research and funding in sarcopenia-related treatments in the future.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Sarcopenia Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Sarcopenia Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Sarcopenia Market - Industry Life Cycle |
3.4 Australia Sarcopenia Market - Porter's Five Forces |
3.5 Australia Sarcopenia Market Revenues & Volume Share, By Supplement Type, 2021 & 2031F |
3.6 Australia Sarcopenia Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Sarcopenia Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing aging population in Australia |
4.2.2 Growing awareness about the health risks associated with sarcopenia |
4.2.3 Rise in demand for nutritional supplements and exercise programs for muscle health |
4.3 Market Restraints |
4.3.1 Limited availability of specialized healthcare services for sarcopenia treatment |
4.3.2 High cost of diagnostic tests and treatment options |
4.3.3 Lack of standardized guidelines for sarcopenia management in Australia |
5 Australia Sarcopenia Market Trends |
6 Australia Sarcopenia Market, By Types |
6.1 Australia Sarcopenia Market, By Supplement Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Sarcopenia Market Revenues & Volume, By Supplement Type, 2021- 2031F |
6.1.3 Australia Sarcopenia Market Revenues & Volume, By Protein Supplement, 2021- 2031F |
6.1.4 Australia Sarcopenia Market Revenues & Volume, By Vitamin D & Calcium Supplement, 2021- 2031F |
6.1.5 Australia Sarcopenia Market Revenues & Volume, By Vitamin B12 Supplement, 2021- 2031F |
6.2 Australia Sarcopenia Market, By Distribution Channel |
6.2.1 Overview and Analysis |
6.2.2 Australia Sarcopenia Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.2.3 Australia Sarcopenia Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.2.4 Australia Sarcopenia Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.2.5 Australia Sarcopenia Market Revenues & Volume, By Hypermarket & Supermarket, 2021- 2031F |
7 Australia Sarcopenia Market Import-Export Trade Statistics |
7.1 Australia Sarcopenia Market Export to Major Countries |
7.2 Australia Sarcopenia Market Imports from Major Countries |
8 Australia Sarcopenia Market Key Performance Indicators |
8.1 Percentage increase in the number of geriatric healthcare facilities offering sarcopenia treatment programs |
8.2 Growth in the number of research studies and clinical trials focused on sarcopenia in Australia |
8.3 Adoption rate of nutritional supplements and exercise programs targeting muscle health in the aging population |
9 Australia Sarcopenia Market - Opportunity Assessment |
9.1 Australia Sarcopenia Market Opportunity Assessment, By Supplement Type, 2021 & 2031F |
9.2 Australia Sarcopenia Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Sarcopenia Market - Competitive Landscape |
10.1 Australia Sarcopenia Market Revenue Share, By Companies, 2024 |
10.2 Australia Sarcopenia Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |